Phenotypic and mechanistic analysis of the in vivo HIV latent reservoir by single-cell technologies
通过单细胞技术对体内 HIV 潜伏病毒库进行表型和机制分析
基本信息
- 批准号:10448398
- 负责人:
- 金额:$ 84.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-08-01 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:AnatomyAntigensAtlasesAutomobile DrivingBackBioinformaticsBiological MarkersBloodCD4 Positive T LymphocytesCell surfaceCellsClinicalClonal ExpansionCytomegalovirusDNA sequencingData AnalysesData SetDevelopmentExhibitsFaceFlow CytometryFluorescenceFrequenciesGene ExpressionGene Expression ProfileGenetic TranscriptionGenomeGoalsHIVHIV GenomeHIV InfectionsHomeostasisImmunologyIndividualInfectionInterventionKnowledgeLeadLengthLeukapheresisLinkLocationMaintenanceMapsMeasuresMethodsMolecularPatientsPersonsPhenotypePopulationPropertyProteinsRegression AnalysisResearchResearch PersonnelResearch PriorityRoleSamplingSorting - Cell MovementSpecificitySurfaceSystemT-LymphocyteT-Lymphocyte SubsetsTechnologyTimeTissuesTranslationsViralViral ProteinsVirusWomanantiretroviral therapybasebiological sexco-infectioncohortdefined contributiondesignexperimental studyhigh dimensionalityin vivolatent HIV reservoirlymph nodesmenmortalitymultidimensional datanovelpatient populationreceptorsexsingle cell analysissingle cell technologysingle-cell RNA sequencingtooltraitviral DNA
项目摘要
PROJECT SUMMARY
Combination antiretroviral therapy (ART) can suppress HIV replication and lead to decreased mortality
in HIV-infected individuals. However, ART does not eliminate the latent HIV reservoir, so effective viral
suppression requires lifelong ART administration. Therefore, developing a way to eliminate or achieve ART-free
control of the reservoir is a top research priority. One challenge to accomplishing this is that we still have limited
understanding of the phenotypic and functional properties of the latently-infected cells that persist in people living
with HIV. One challenge to characterizing in vivo latently-infected cells is the inability to directly phenotype these
cells, due to the lack of a universal biomarker distinguishing them from uninfected cells. As a result, the only way
to directly phenotype latent cells has been to stimulate a bulk population of patient-derived cells ex vivo in order
to induce expression of viral proteins by the latent cells. Although this allows identification and therefore
phenotyping of the reactivated cells by FACS, the measured phenotypes are different from the original
phenotypes of the latently-infected cells since ex vivo stimulation alters gene expression. Here, by applying a
pseudotime-based bioinformatics approach called PP-SLIDE on paired sets of unstimulated and stimulated
patient cells deep-phenotyped by high-dimensional single-cell analytical approaches (CyTOF, single-cell
RNAseq), we infer the phenotypes of latently-infected cells in their original pre-stimulation state, and use this
approach to chart the in vivo latent reservoir. In Aim 1, we will use PP-SLIDE on CyTOF-phenotyped cells to
compare the latently-infected cells present in the blood and tissues of clinically-matched men and women. In
Aim 2, we will characterize the extent to which markers identified in Aim 1, as well as markers identified from an
unbiased approach implementing PP-SLIDE on cells analyzed by single-cell RNAseq, enrich for reservoir cells
harboring HIV with genetically-intact replication-competent HIV, for these are the cells that are likely the most
important to control or eliminate for ART-free viral control. In Aim 3, we will characterize the mechanisms that
allow the latently-infected cells to persist, focusing on the role of antigen- and homeostasis-driven clonal
expansion of CD4+ T cells. By combining cutting-edge single-cell analysis tools with high-dimensional data
analysis methods to map the “atlas” of in vivo latent cells, our studies will provide an unprecedented definition of
the features of reservoir cells that persist, reveal whether any reservoir cell traits associate with anatomy (blood
vs. tissues) or biological sex (men vs. women), and inform on the mechanisms driving reservoir maintenance.
This knowledge that will be important for designing targeted methods to achieve a universal HIV cure.
项目概要
联合抗逆转录病毒疗法 (ART) 可抑制 HIV 复制并降低死亡率
在艾滋病毒感染者中。然而,ART 并不能消除潜伏的 HIV 病毒库,因此有效的病毒
抑制需要终生 ART 治疗。因此,开发一种方法来消除或实现无 ART
水库的控制是研究的重中之重。实现这一目标的一个挑战是我们的资源仍然有限
了解人们体内持续存在的潜伏感染细胞的表型和功能特性
患有艾滋病毒。表征体内潜伏感染细胞的一项挑战是无法直接对这些细胞进行表型分析
细胞,由于缺乏将它们与未感染细胞区分开的通用生物标志物。结果,唯一的办法就是
直接对潜伏细胞进行表型分析是在体外刺激大量患者来源的细胞,以便
诱导潜伏细胞表达病毒蛋白。尽管这允许识别,因此
通过FACS对重新激活的细胞进行表型分析,测得的表型与原始细胞不同
由于离体刺激改变了基因表达,因此潜伏感染细胞的表型。在这里,通过应用
基于伪时间的生物信息学方法,称为 PP-SLIDE,针对未刺激和刺激的配对组
通过高维单细胞分析方法(CyTOF、单细胞
RNAseq),我们推断潜伏感染细胞在原始刺激前状态的表型,并使用此
绘制体内潜在储库图的方法。在目标 1 中,我们将在 CyTOF 表型细胞上使用 PP-SLIDE
比较临床匹配的男性和女性血液和组织中存在的潜伏感染细胞。在
目标 2,我们将描述目标 1 中识别的标记以及从目标 1 中识别的标记的程度。
对单细胞 RNAseq 分析的细胞实施 PP-SLIDE 的无偏方法,富集储存细胞
携带 HIV 且具有基因完整且具有复制能力的 HIV 的细胞,因为这些细胞可能是最容易被感染的细胞。
对于无 ART 病毒控制而言,控制或消除非常重要。在目标 3 中,我们将描述以下机制:
让潜伏感染的细胞持续存在,重点关注抗原和稳态驱动的克隆的作用
CD4+ T 细胞的扩增。通过将尖端的单细胞分析工具与高维数据相结合
分析方法来绘制体内潜伏细胞的“图谱”,我们的研究将为
储存细胞持续存在的特征揭示了是否有任何储存细胞特征与解剖学(血液)相关
与组织)或生物性别(男性与女性),并了解驱动水库维护的机制。
这些知识对于设计有针对性的方法以实现艾滋病毒的普遍治愈非常重要。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nadia R Roan其他文献
Transient Anti-Interferon Auto Antibodies in the Airway Are Associated with Recovery in Mild COVID-19
- DOI:
10.1182/blood-2023-190358 - 发表时间:
2023-11-02 - 期刊:
- 影响因子:
- 作者:
Benjamin R Babcock;Astrid Kosters;Nadia R Roan;Sulggi Lee;Eliver E.B. Ghosn - 通讯作者:
Eliver E.B. Ghosn
Nadia R Roan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Nadia R Roan', 18)}}的其他基金
Reservoir features associated with time-to-rebound during analytical treatment interruption
与分析处理中断期间的反弹时间相关的储层特征
- 批准号:
10459934 - 财政年份:2022
- 资助金额:
$ 84.35万 - 项目类别:
Characterizing ART-free NK cell-mediated control of HIV infection in people living with HIV
描述 HIV 感染者中无 ART 的 NK 细胞介导的 HIV 感染控制
- 批准号:
10535192 - 财政年份:2022
- 资助金额:
$ 84.35万 - 项目类别:
Characterizing ART-free NK cell-mediated control of HIV infection in people living with HIV
描述 HIV 感染者中无 ART 的 NK 细胞介导的 HIV 感染控制
- 批准号:
10671559 - 财政年份:2022
- 资助金额:
$ 84.35万 - 项目类别:
Reservoir features associated with time-to-rebound during analytical treatment interruption
与分析处理中断期间的反弹时间相关的储层特征
- 批准号:
10614027 - 财政年份:2022
- 资助金额:
$ 84.35万 - 项目类别:
Phenotypic and mechanistic analysis of the in vivo HIV latent reservoir by single-cell technologies
通过单细胞技术对体内 HIV 潜伏病毒库进行表型和机制分析
- 批准号:
10357547 - 财政年份:2019
- 资助金额:
$ 84.35万 - 项目类别:
Phenotypic and mechanistic analysis of the in vivo HIV latent reservoir by single-cell technologies
通过单细胞技术对体内 HIV 潜伏病毒库进行表型和机制分析
- 批准号:
10360854 - 财政年份:2019
- 资助金额:
$ 84.35万 - 项目类别:
Project 1: Using CyTOF to identify phenotypic and functional biomarkers predicting time to HIV rebound after treatment interruption
项目 1:使用 CyTOF 识别表型和功能生物标志物,预测治疗中断后 HIV 反弹的时间
- 批准号:
10223995 - 财政年份:2017
- 资助金额:
$ 84.35万 - 项目类别:
Exploiting the Host-HIV Interface To Identify Biomarkers Predicting Time to Viral Rebound after Treatment Interruption
利用宿主-HIV 界面识别生物标志物,预测治疗中断后病毒反弹的时间
- 批准号:
10223991 - 财政年份:2017
- 资助金额:
$ 84.35万 - 项目类别:
Characterization of Exosomes From Semen of Uninfected and HIV-Infected Men
未感染和 HIV 感染男性精液中外泌体的表征
- 批准号:
9228315 - 财政年份:2016
- 资助金额:
$ 84.35万 - 项目类别:
Characterization of Exosomes From Semen of Uninfected and HIV-Infected Men
未感染和 HIV 感染男性精液中外泌体的表征
- 批准号:
9062790 - 财政年份:2016
- 资助金额:
$ 84.35万 - 项目类别:
相似国自然基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
- 批准号:2022J011295
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
- 批准号:30801055
- 批准年份:2008
- 资助金额:19.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
- 批准号:
BB/Y006224/1 - 财政年份:2024
- 资助金额:
$ 84.35万 - 项目类别:
Research Grant
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
- 批准号:
480030 - 财政年份:2023
- 资助金额:
$ 84.35万 - 项目类别:
Operating Grants
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
- 批准号:
10083718 - 财政年份:2023
- 资助金额:
$ 84.35万 - 项目类别:
Small Business Research Initiative
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
- 批准号:
MR/X009254/1 - 财政年份:2023
- 资助金额:
$ 84.35万 - 项目类别:
Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
- 批准号:
22KJ1758 - 财政年份:2023
- 资助金额:
$ 84.35万 - 项目类别:
Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
- 批准号:
BB/Y000927/1 - 财政年份:2023
- 资助金额:
$ 84.35万 - 项目类别:
Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
- 批准号:
10795212 - 财政年份:2023
- 资助金额:
$ 84.35万 - 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
- 批准号:
23K18249 - 财政年份:2023
- 资助金额:
$ 84.35万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
- 批准号:
10735075 - 财政年份:2023
- 资助金额:
$ 84.35万 - 项目类别:
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
- 批准号:
10645989 - 财政年份:2023
- 资助金额:
$ 84.35万 - 项目类别:














{{item.name}}会员




